A Case Report for Acute Myopericarditis After NVX-CoV2373 (Novavax®) COVID-19 Vaccination
10.3346/jkms.2022.37.e265
- Author:
Hyung Yoon KIM
1
;
Jae Yeong CHO
;
Hyun Ju YOON
;
Yoo-Duk CHOI
;
Youngkeun AHN
;
Myung Ho JEONG
;
Jeong Gwan CHO
;
Kye Hun KIM
Author Information
1. Department of Cardiovascular Medicine, Chonnam National University Medical School/Hospital, Gwangju, Korea
- Publication Type:Case Report
- From:Journal of Korean Medical Science
2022;37(34):e265-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Post-vaccination myocarditis after administration of the NVX-CoV2373 coronavirus disease 2019 (COVID-19) vaccine has been reported in a limited population. We report the first biopsy-proven case of myopericarditis after administration of second dose of NVX-CoV2373 COVID-19 vaccine (Novavax®) in Korea. A 30-year-old man was referred to emergency department with complaints of chest pain and mild febrile sense for two days. He received the second dose vaccine 17 days ago. Acute myopericarditis by the vaccination was diagnosed by cardiac endomyocardial biopsy. He was treated with corticosteroid 1 mg/kg/day for 5 days and tapered for one week. He successfully recovered and was discharged on the 12th day of hospitalization. The present case suggests acute myopericarditis as a vaccination complication by Novavax® in Korea.
